|Sennoside A Irritant laxative;mild MAO inhibitor|
Sample solution is provided at 25 µL, 10mM.
Publications citing ApexBio Products
Related Compound Libraries
|Cas No.||81-27-6||SDF||Download SDF|
|Chemical Name||(9R)-9-[(9R)-2-carboxy-4-hydroxy-10-oxo-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracen-9-yl]-4-hydroxy-10-oxo-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracene-2-carboxylic acid|
|Solubility||>39.9mg/mL in DMSO||Storage|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.|
|Shipping Condition||Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
Sennoside A is a dianthrone glycoside isolated from Rhei Rhizoma and senna leaf. Sennoside A and B have identical molecular weights and formulae. Sennosides were known as laxatives causing purgative actions through the biotransformation of rhein anthrone. Sennoside A was reported to have regionally differential effects on spontaneous contractions of colon.
In vitro: The gastroprotective activities of sennoside A was found to be due to the up-regulation of PGE2 and the inhibitions of H+/K+-ATPase activity. When measured the H+/K+-ATPase activities of sennoside A, the positive control exhibited inhibitions of 41.1% and 42.4% at 50 μM and 100 μM, whereas sennoside A showed dose-dependent inhibitions of 17.3% and 27.1% at 50 μM and 100 μM .
In vivo: In a rat model, sennoside A reduced gastric juice, total acidity and increased pH, indicating that proton pump inhibition reduces gastric acid secretion. Furthermore, sennoside A increased PGE2 in a concentration-dependent manner. Moreover, in the intestinal transporting and gastric emptying rate experiment, sennoside A was found to accelerate such GI motility. These results suggested sennoside A possessed significant gastroprotective activities and it might be useful for the gastric disease treatment .
Clinical trial: N/A
 In Young HwangandChoon Sik Jeong. Gastroprotective Activities of Sennoside A and Sennoside B via the Up-Regulation of Prostaglandin E2and the Inhibition of H+/K+-ATPase Biomol Ther (Seoul). 2015 Sep; 23(5): 458–464.